Ocugen has given investors a fresh look under the hood of its gene therapy pipeline — and in doing so, quietly changed the yardstick by which its lead program will be judged. In a presentation to investors and analysts, the Pennsylvania-based biotech confirmed that 140 patients have now been enrolled in liMeliGhT, the pivotal Phase 3 trial of OCU400. More consequential for the regulatory pathway: the primary endpoint will now be measured using LDNA rather than MLMT. Topline data from the study are penciled in for the first quarter of 2027.
The same SEC filing that carried those details also sketched out the road ahead for OCU410, pairing Phase 2 results with design considerations for future late-stage testing. Yet the clinical news landed against a sobering backdrop on the trading floor. Ocugen shares changed hands at EUR 0.7200, within touching distance of their 52-week low of EUR 0.7010, and have shed 43% since the start of the year.
A MENA Licence With Real Numbers Attached
Alongside the trial update, Ocugen fleshed out the economics of its exclusive licensing pact with Roots Pharmaceutical for OCU400 across the Middle East and North Africa. The agreement carries upfront and development payments of as much as $4 million, with milestone payments of up to $255 million contingent on hitting defined sales thresholds. On top of that, Ocugen stands to collect royalties equal to 22% of net sales in the licensed territory, while retaining responsibility for manufacturing and supplying the therapy.
Those headline figures come with a long fuse. Revenue depends on regulatory approvals and commercial uptake that remain years away, leaving the arrangement far short of what a clinical-stage biotech needs to plug its ongoing funding requirements.
Should investors sell immediately? Or is it worth buying Ocugen?
Insider Sales and a Delayed Shareholder Vote
Sentiment has also been dented by activity at the top of the company. CEO and Director Shankar Musunuri offloaded a combined 525,991 shares on 9 October through direct and indirect holdings, including 468,727 shares held directly and a further 57,264 held indirectly via KVM Holdings, LLC. The transactions were executed under a Rule 10b5-1 trading plan adopted on 5 June 2026 — a mechanical, pre-scheduled arrangement rather than a discretionary call. Even so, investors rarely read insider selling as a vote of confidence.
Adding to the caution is a postponed vote on authorised share capital, a topic that puts the prospect of dilution squarely on the table. The delay underscores how heavily Ocugen’s outlook rests on future financing steps.
What the Market Is Really Pricing
The company has done what it can to keep its story moving: trial enrolment is complete, the endpoint methodology has been sharpened, and a regional partner has signed on for OCU400. What it has not done is answer the question weighing on the share price — how the balance sheet gets from here to a 2027 data readout. Until that gap closes, royalties from the Middle East and North Africa are unlikely to shift the narrative on their own.
Ad
Ocugen Stock: Buy or Sell?! New Ocugen Analysis from October 20 delivers the answer:
The latest Ocugen figures speak for themselves: Urgent action needed for Ocugen investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 20.
Ocugen: Buy or sell? Read more here...
